Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Nitisinone, a drug that is already used to treat two genetic diseases, could be repurposed to control the spread of malaria, ...

Tyrosine, a non-essential amino acid, is vital for the production of neurotransmitters like dopamine, norepinephrine, and epinephrine. These neurotransmitters play an essential part in regulating ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency.

The molecular basis of phospho-tyrosyl-regulation of Src-family and Syk-family protein tyrosine kinases in signaling pathways is a current focus of the lab. The conformational activation of Src kinase ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...